SEP 0 5 2006 Ap

INFORMATION DISCLOSURE STATEMENT

Applicant

Carlton et al.

App. No

10/659,698

Filed

September 11, 2003

For

ANTIBACTERIAL THERAPY WITH

BACTERIOPHAGE PHYSICO-CHEMICALLY ALTERED BY PEGYLATION TO DELAY INACTIVATION BY THE HOST

DEFENSE SYSTEM

Examiner

Snyder, Stuart

Art Unit

1648

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 4 references to be considered by the Examiner. Also enclosed are 4 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed with an RCE and no fee is required.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated:	17700

0011100

By:

Registration No. 36,298

Attorney of Record

Customer No. 45,311

(805) 547-5580

IDS 2883241:vb 082906

PTO/SB	/08	Fouiva	lent

**************************************		PTO/SB/08 Equivale
EP 0 5 2006	Application No.	10/659,698
INF RMATION DISCLOSURE	Filing Date	September 11, 2003
TATEMENT BY APPLICANT	First Named Inventor	Carlton et al.
TATEINENT BY APPLICANT	Art Unit	1648
(Multiple sheets used when necessary)	Examiner	Snyder, Stuart
SHEET 1 OF 1	Attorney Docket No.	NIH297.1C1C1C1

	U.S. PATENT DOCUMENTS				
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		- 			

	FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹	
	1	Chillon et al. "Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro." Gene Ther 5: 995 (1998).		
	2	O'Riordan et al. "PEGylation of Adenovirus with Retention of Infectivity and Protection from Neutralizing Antibody in Vitro and in Vivo." Hum Gene Ther 10: 1349 (May 1999).		
	3	Romanczuk et al. "Modification of an Adenoviral Vector with Biologically Selected Peptides: A Novel Strategy for Gene Delivery to Cells of Choice." Hum Gene Ther 10: 2615 (Nov 1999).		
	4	Delgado et al. "Coupling of Poly(ethylene glycol) to Albumin under Very Mild Conditions by Activation with Tresyl Chloride: Characterization of the Conjugate by Partitioning in Aqueous Two-Phase Systems." Biotechnol Appl Biochem 12: 119 (1990).		

2883267:vb 082906

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.